

## **Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021**

Paul Kuodi<sup>1</sup>, Yanay Gorelik<sup>1</sup>, Hiba Zayyad<sup>1,3</sup>, Ofir Wertheim<sup>3</sup>, Karine Beirut Wiegler<sup>2</sup>, Kamal Abu Jabal<sup>1,2</sup>, Amiel A. Dror<sup>1,4</sup>, Saleh Nazzal<sup>3</sup>, Daniel Glikman<sup>1,3</sup>, Michael Edelstein<sup>1,2</sup>

Authors' affiliations:

<sup>1</sup>Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

<sup>2</sup>Ziv Medical Centre, Safed, Israel

<sup>3</sup>Baruch Padeh Medical Centre, Poriya, Israel

<sup>4</sup>Galilee Medical Centre, Nahariyah, Israel

Correspondence to:

Paul Kuodi: [kuodipa@biu.ac.il](mailto:kuodipa@biu.ac.il)  
The Azrieli Faculty of Medicine  
Bar-Ilan University  
8 Henrietta Szold St, Safed  
Israel.

## Abstract

**Background:** Long COVID is a post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection syndrome characterised by not recovering for several weeks or months following the acute episode. The effectiveness of COVID-19 vaccines against long-term symptoms of COVID19 is not well understood. We determined whether vaccination was associated with reporting long-term symptoms post-SARS-CoV-2 infection by comparing, among individuals previously infected with SARS-CoV-2, those who were vaccinated to those who were not, in terms of self-reported long-term symptoms.

**Methods:** We invited individuals who were PCR tested for SARS-CoV-2 infection at participating hospitals between March 2020-June 2021 to fill an online questionnaire that included baseline demographics, details of their acute episode and information about symptoms they were currently experiencing. Using binomial regression, we compared vaccinated individuals with those unvaccinated in terms of self-reported symptoms post-acute infection.

**Results:** Of 951 previously infected individuals who filled the survey 637(67%) were vaccinated. The most commonly reported symptoms were; fatigue (22%), headache (20%), weakness (13%), and persistent muscle pain (10%). After adjusting for follow-up time and baseline symptoms, fully vaccinated (2 or more doses) individuals were less likely than unvaccinated individuals to report any of these symptoms by 64%, 54%, 57%, and 68% respectively, (Risk ratios 0.36, 0.46, 0.43, 0.32,  $p < 0.04$  in the listed sequence).

**Conclusions:** Vaccination with at least two doses of COVID-19 vaccine was associated with a substantial decrease in reporting the most common post-acute COVID19 symptoms. Our results suggest that, in addition to reducing the risk of acute illness, COVID-19 vaccination may have a protective effect against long COVID.

## Introduction

Long coronavirus disease 2019 (Long COVID), also known as post-COVID-19 syndrome, is an emerging and complex health problem that remains poorly characterised. In October 2021, the World Health Organization (WHO) defined long COVID as “A condition which occurs in individuals with a history of probable or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, usually three months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction but also others involving the musculo-skeletal, cardiac and central nervous systems, which generally have an impact on everyday functioning” [1]. Symptoms of long COVID may fluctuate or relapse over time. Patients purported to have long COVID have reported a wide range of symptoms but the most prevalent symptoms include; fatigue (approximately 58%), shortness of breath (24%), joint pain (19%), chest pain (16%) [2, 3], headache (44%), palpitations (11%), physical limitations, depression (12%) and insomnia (11%) [3, 4]. These symptoms may emerge after the initial recovery from an acute COVID-19 episode, or be persistent symptoms that do not resolve following the initial COVID-19 illness [5].

Vaccination against SARS-CoV-2 infection is one of the most important interventions deployed to mitigate the COVID-19 pandemic. As of October 2021, the WHO has listed the Pfizer/BioNTech, AstraZeneca-SK Bio, Sinopharm, Serum Institute of India, Janssen, and Moderna vaccines for emergency use under the Emergency Use Authorisation (EUA) [6]. In August 2021, the Food and Drugs Administration (FDA) approved the Pfizer/BioNTech vaccine as the first vaccine for use to prevent COVID-19 in individuals sixteen years and older [7].

The first COVID-19 vaccine campaign with a WHO-approved vaccine started in December 2020, following the authorisation of the Pfizer/BioNTech mRNA vaccine by the FDA for emergency use. By January 2022, over 58% of the world population had received at least one dose of the EUA COVID-19 vaccines, accounting for 9.2 billion COVID-19 doses [8]. Available evidence demonstrates that COVID-19 vaccines are effective in preventing severe complications of COVID-19 and death

[9], including in cases of infection with the Delta and Omicron variants of SARS-CoV-2 [10-12], variants that are more contagious than the ancestral SARS-CoV-2 variants [12,13]. In Israel, the COVID-19 vaccination campaign started in December 2020, and by January 2022, approximately 63.6% of the entire population had received a priming, two-dose course, mainly with the BNT162b2 mRNA vaccine [14] and 45.6% had received a third dose of COVID-19 vaccines, available in Israel from June 2021. The third dose demonstrated high effectiveness against severe outcomes in the context of waning immunity six months post-priming course [14]. During the study period, individuals previously infected with SARS-CoV-2 were eligible for a single dose of the BNT162b2 mRNA vaccine. All other individuals with no history of SARS-CoV-2 infection were eligible for a first and a second dose with eligibility for the second dose at three weeks from the date of the first dose.

Risk factors for developing long COVID have not been fully explored. So far, increasing age, pre-existing health conditions such as hypertension, obesity, psychiatric disorders, and immunosuppression have been associated with an increased risk of long COVID [15]. As the process to establish a more specific case definition of long COVID continues, little is known about the impact of COVID-19 vaccination on long COVID. A large prospective study reported an association between vaccination and lower self-reporting of symptoms beyond 28 days among SARS-CoV-2 infected individuals without reporting details on specific symptoms or duration [16]. Findings from one study (in preprint) suggests vaccination reduces the reporting of some, but not all post-acute COVID-19 sequelae 6 months post-infection [17]. Another study, albeit with a small sample and without a control group, reported a high proportion of COVID-19 breakthrough infections among patients with long COVID symptoms [18]. An additional study reported that 20% of individuals infected post-vaccination developed post-COVID-19 symptoms beyond 6 weeks, however the investigators did not carry out baseline comparisons [19]. In the current study, we aimed to determine whether vaccination status was associated with reporting specific long-term symptoms post-COVID-19 infection by comparing, among individuals previously infected with SARS-CoV-2, those who were vaccinated to those who were not in terms of self-reported long-term symptoms.

## **Methods**

### **Study design and participants**

The current study reports results of a cross-sectional study nested in a prospective longitudinal cohort study to assess risk of and risk factors for long-term physical, mental, and psychosocial consequences of COVID-19. All individuals over the age of 18 who were tested for SARS-CoV-2 infection by reverse transcription polymerase chain reaction (RT-PCR) between 15<sup>th</sup> March 2020 and 15<sup>th</sup> June 2021 in the three major government hospitals in Northern Israel, namely Ziv Medical Centre, Padeh-Poriya Medical Centre, and Galilee Medical Centre, were eligible to join the study regardless of the test result. Using available patient telephone records, individuals were invited to participate in the study between July 16<sup>th</sup> and November 18<sup>th</sup> 2021, through a Short Message Service (SMS) containing an invitation with a link to an online survey available in four commonly spoken languages in Israel: Hebrew, Arabic, Russian, and English. Two reminders to complete the survey were sent to non-responders. For the purposes of this study, we restricted the analysis to individuals who reported being infected with SARS-CoV-2 and diagnosed by PCR.

### **Measurement tools**

The data collection tool was modified from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 tools developed by a global follow-up working group and informed by a wide range of global stakeholders with expertise in clinical research, outbreak research, infectious disease, epidemiology, respiratory, critical care, rehabilitation, neurology, psychology, rheumatology, cardiology, oncology, and public health medicine [20]. The ISARIC questionnaire was adapted to the Israeli context. Study participants were asked to select from a list all symptoms they were currently experiencing.

### **Data collected**

The online survey included information about socio-demographic status (place of residence, age, sex, ethnicity/religious affiliation, education level and income), baseline health status: (Body mass index [BMI] and chronic conditions), information related to the clinical experience and symptoms experienced during the initial COVID-19 diagnosis, SARS-CoV-2 test results, vaccination status, number of doses, type of vaccine and date of administration. Participants were also asked to report symptoms experienced at the time of filling the questionnaire. A simplified paper version of the questionnaire can be found in Appendix 1.

## **Outcomes**

The primary outcome in this study was the proportion, overall, and in specific age groups, of previously infected participants reporting selected health outcomes among the vaccinated compared to the unvaccinated individuals. Vaccinated individuals were infected either before or after vaccination. The complete list of symptoms can be found in Table 1.

## **Statistical analysis**

We compared the vaccinated and unvaccinated groups' socio-demographic and health characteristics using Chi-square tests (for proportions) and Student's t-tests (for means). We also compared symptoms at presentation using Chi-square tests. Proportions of long-term symptoms and selected health outcomes were calculated for each group with the total number of participants in each group taken as the denominator. We also compared the time elapsed between the onset of COVID-19 symptoms for symptomatic patients and the date of response to the survey in the two groups (vaccinated and unvaccinated) to establish whether they had comparable durations of follow-up.

A series of binary regression models were fitted to the data for the ten most commonly reported post-COVID-19 symptoms according to vaccination status. We adjusted for the difference in follow-up time and proportion of asymptomatic patients at the time of diagnosis between the groups. In addition, to take the anticipated age differences into account, the analysis was age-stratified and differences in the length

of time from the beginning of symptoms to responding to the survey were adjusted for in the model. Vaccination status was recorded as either unvaccinated, partial (one dose) or complete (two or more doses). Datasets were processed using Microsoft Excel and analysed using STATA version 15.

### **Ethical considerations**

The study received ethical approvals from the Ziv Medical Centre, Padeh-Poriya Medical Centre, and Galilee Medical Centre ethical committees, reference numbers; 0007-21-ZIV, 009-21-POR, and 0018-21-NHR, respectively.

### **Role of the funding source**

No specific funding was received for this study

## **Results**

### **Characteristics of the study population**

Of 30,262 invitations to participate in the study, 2346 (7.8%) individuals responded to the survey and agreed to participate. Of these, 951 individuals reported testing positive for SARS-CoV-2 by PCR and were therefore included in the study.

Of these, 634 (67%) reported having received at least one dose of a COVID-19 vaccine. Of the vaccinated participants, 340 (53%) reported receiving a single dose and 294 (47%) reported being fully vaccinated (two or more doses of COVID-19 vaccine). Of the 951 individuals, 636 (67%) reported at least one symptom during COVID-19 diagnosis. Among the unvaccinated, 69% reported at least one symptom at COVID-19 diagnosis, vs. 57% among the fully vaccinated and 74% among the partially vaccinated, ( $p < 0.05$ , Table 1). Additionally, the reported symptoms were less frequent at the time of SARS-CoV-2 PCR testing among the fully vaccinated compared to the partially vaccinated and the unvaccinated (Figure 1A).

Compared with fully and partially vaccinated individuals, unvaccinated participants were younger (52 and 44 vs. 39 years, respectively,  $p < 0.001$ , Table 1), reflecting the COVID-19 vaccination patterns in the general population. Consequently, pre-existing chronic conditions were more frequently reported in the vaccinated group ( $p < 0.05$ ). The vaccinated and unvaccinated groups were comparable in terms of gender

distribution and socio-economic characteristics (Table 1). The median time between acute illness and reporting symptoms was longer in the unvaccinated group compared to the fully vaccinated (8 vs. 4 months,  $p < 0.05$ ). Out of 951 participants, 85 (9%) reported having been hospitalized with comparable proportions in the fully vaccinated, partially vaccinated and the unvaccinated ( $p = 0.27$ , Table 1).

### **Post-COVID-19 symptoms among vaccinated and unvaccinated participants**

Of the 951 participants, 337 (35%) reported not fully recovering from the initial COVID-19 symptoms at follow-up. The most commonly reported symptoms at the time of follow-up were fatigue (22%), headache (20%), and weakness in arms or legs (13%) (Table 2, Figure 1B).

### **Risk of reporting post-COVID-19 symptoms according to vaccination status**

Compared with unvaccinated participants, those fully vaccinated were 36-73% less likely to report eight of the ten most commonly reported symptoms ( $p < 0.04$  for all, Table 3). After adjusting for duration of follow-up and presence of symptoms at baseline, a 54-82% reduction in reporting symptoms among those fully vaccinated for seven of the ten most commonly reported symptoms was detected (Table 3). In the unadjusted age-stratified analysis, differences in reported symptoms were primarily seen in the older age groups, in particular those aged above 60 years who were also 68% more likely to report feeling fully recovered compared with their unvaccinated peers of the same age (Table 3,  $p < 0.004$ ). Although the risk ratio remained high in the adjusted analysis (RR 1.7), the result was no longer significant, likely due to loss of statistical power.

### **Discussion**

Overall, full vaccination (2 or more vaccines) was associated with a substantial decrease in reporting the most common post-COVID-19 symptoms, and an increase in reporting full recovery, specifically in individuals aged above 60 years. These associations were largely not seen among individuals who received a single dose of a COVID-19 vaccine. The results are consistent with the few other available studies



on the topic [17,19,21] and bring previously unavailable nuance on the effect of vaccination on reported long-term symptoms, both in terms of symptom specificity and time from acute infection. Approximately a third of participants in the current study continued to report post-COVID-19 symptoms, mostly fatigue, headache, and weakness. Our findings are consistent with a recently published study reporting similar proportions of post-COVID-19 symptoms [22]. An age-stratified analysis showed that the associations reported in the current study were largely confined to older age groups (above 60 years), a finding not consistent with a previous study reporting that the protective effect was confined to younger age groups [17]. Our analysis does not allow us to establish why the beneficial effect of the COVID-19 vaccine on long-term symptoms seems to be stronger in older age groups. A plausible explanation for the association found in the older individuals could be that younger individuals have more physiological reserve and are therefore able to recover on their own, which is not the case in older adults. Other studies have reported that frailty was associated with both age and worse outcomes following SARS-CoV-2 infection [23].

The unvaccinated and the vaccinated groups were comparable in sociodemographic characteristics except for age, reflecting vaccine coverage in the Israeli population [24]. As a result, some chronic conditions present at baseline were more common in the vaccinated group. However, since these conditions are more common in the older fully vaccinated group, we would anticipate even bigger differences between the vaccinated and unvaccinated group had we taken them into account in the analysis. This difference in age between the vaccinated and the unvaccinated individuals is consistent with the COVID-19 vaccination strategy implemented by the Israeli Ministry of Health, which targeted the older population during the initial stages of the COVID-19 vaccination rollout. The vaccinated and unvaccinated populations differed in terms of distribution of symptoms and proportion of asymptomatic individuals at acute COVID-19 presentation. A higher proportion of fully vaccinated group were asymptomatic at the time of diagnosis compared to the unvaccinated group, and those who were symptomatic at baseline reported less symptoms compared with those unvaccinated. These figures reflect the protection against symptomatic disease conferred by vaccines, which may also partly explain the lower proportion of reporting long-term symptoms among those vaccinated. However, the

protective effect of vaccination against long term symptoms persisted after adjusting for asymptomatic disease, suggesting a reduction in reported long COVID symptoms even among those symptomatic at the time of infection. The median follow-up duration was longer in the unvaccinated group than the vaccinated individuals. One could therefore expect less symptoms in the unvaccinated as a result of having a longer time period to recover; however, the opposite was observed, and in any case the protective effect of vaccination remained after adjusting for follow up time. The adjusted model suggested an even stronger protective effect of vaccination against reported long-term symptoms. However, we believe that the study was underpowered to detect age specific differences using an adjusted regression model.

Our study relied on self reported positive PCR results. In Israel, most individuals have been PCR-tested multiple times for a range of reasons including being symptomatic, travelling, contact tracing, and screening. Specimens for the same patients are tested in different laboratories. Therefore, using positive lab results from a selection of laboratories (rather than all laboratories in the country) could lead to misclassification. Considering the consequences on daily life, including quarantine, It is unlikely that someone would forget having tested positive for SARS-CoV-2, or vice versa. It is also important to note that the vaccination policy in Israel, at the time of the survey, specified that SARS-CoV-2-infected individuals were in theory only eligible for a single dose of vaccine. Therefore, individuals who were partially vaccinated also differed from those fully vaccinated in terms of the sequence of events: while those who received two doses will have mostly been infected after having been fully vaccinated, many among those who received a single dose will have been infected prior to vaccination. Although our data does not allow to establish this sequence of events for each individual, the follow up time and symptoms at presentation reflect this difference. Infection prior to vaccination could partially explain the observed lack of effect of one dose of vaccine regarding long-term reported symptoms. The effect of vaccination on long-term sequelae according to the infection/vaccination sequence warrants further research. With few patients reporting having been hospitalised, our cohort reflects the mild end of the COVID-19 spectrum, and the results cannot necessarily be extrapolated to patients who were more severely ill (and hospitalised) in the acute phase of the illness. Our study did not include children who are less likely to develop severe acute illness following

infection but do report long-term effects [25]. Prevention of long-term symptoms could be one of the most important benefits of vaccination in this age group. At the time of this study, children were not eligible for COVID-19 vaccines in Israel. A final limitation is the self-reported nature of the symptoms, in particular since individuals who are eager to vaccinate may differ from those who do not vaccinate in terms of perceptions of health and illness.

This study offers a snapshot of the effectiveness of COVID-19 vaccine on the long-term effects of SARS-CoV-2 infection. The findings suggest that in addition to preventing severe disease and death [26], COVID-19 vaccines, or at least the BNT162b2 mRNA vaccine used in Israel, may play a useful role in preventing long-term outcomes of SARS-CoV-2 infection that fit within the current WHO definition of long COVID, in particular among older adults. Studies such as this one should be complemented by studies objectively measuring long-term health outcomes in COVID-19 patients in a clinical setting. Our cohort, which continues to recruit participants, will enable us to report with more precision whether the BNT162b2 mRNA protective effect reported in this study is sustained, as well as the effect of the different SARS-CoV-2 variants and vaccination on post-COVID symptoms.

**Acknowledgements:** We wish to thank Yehudit Hakmon, Eliran Levi, Zion Levi, Nissim Neeman (Ziv Medical Centre), Mark Lifshitz, and Shelly Shalem (Galilee Medical Centre) for their technical help and support in disseminating the questionnaire.

## References

1. World Health Organisation (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021. WHO/2019-nCoV/Post\_COVID-19\_condition/Clinical\_case\_definition/2021.1. Accessed from: <https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/grc-750263>. (accessed December 17<sup>th</sup>, 2021).
2. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA*. 2020 Aug 11;324(6):603-5. doi:10.1001/jama.2020.12603
3. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. Available at SSRN 3769978. 2021 Jan 1.
4. Lancet T. Facing up to long COVID. *Lancet* 2020;396 (10266):1861

5. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: The persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. *Front Med*. 2021 May 4;8:392.
6. World Health Organization. Covax-working for global equitable access to COVID-19 vaccines. 2021. <https://www.who.int/initiatives/act-accelerator/covax>. (accessed December 17<sup>th</sup>, 2021).
7. Tanne JH. Covid-19: FDA approves Pfizer-BioNTech vaccine in record time. *BMJ*. 2021;374:n2096. doi:10.1136/bmj.n2096
8. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. A global database of COVID-19 vaccinations. *Nat Hum Behav*. 2021 May 10:1-7.
9. Henry DA, Jones MA, Stehlik P, Glasziou PP. Effectiveness of COVID-19 vaccines: findings from real world studies. *Med J Aust*. 2021 Aug;215(4):149.
10. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, De Lusignan S. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet*. 2021 May 1;397(10285):1646-57.
11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021 Apr 15;384(15):1412-23.
12. Collie S, Champion J, Moultrie H, Bekker L, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *N Engl J Med*. 2021 Dec 29
13. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, Whittaker C, Mellan T, Ferreira I, Datir R, Collier DA. SARS-CoV-2 B. 1.617. 2 Delta variant emergence and vaccine breakthrough.
14. Muhsen K, Cohen D. COVID-19 vaccination in Israel. *Clin Microbiol Infect*. 2021 Nov 1;27(11):1570-4.
15. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *The Lancet*. 2021 Oct 29.
16. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins C, Kwong AS, Silverwood R, Di Gessa G, Bowyer RC. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. *MedRxiv*. 2021 Jan 1.
17. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham MS, Klaser K, Modat M, Murray B. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases*. 2021 Sep 1.

18. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K, Sapey E. Symptoms, complications and management of long COVID: a review. *J R Soc Med*. 2021 Sep;114(9):428-42.
19. Hoque A, Rahman MM, Imam H, Nahar N, Chowdhury FU. Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections. *medRxiv*. 2021 Jan 1.
20. Lee C, Frishman WH. Implications of frailty in COVID-19. *Cardiol Rev*. 2021 Nov;29(6):285.
21. Sigfrid L, Cevik M, Jesudason E, Lim WS, Rello J, Amuasi J, Bozza F, Palmieri C, Munblit D, Holter JC, Kildal AB. What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. *BMJ open*. 2021 Mar 1;11(3):e043887.
22. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. *medRxiv*. 2021 Jan 1.
23. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG, Rubin C, Indenbaum V, Tal I. Covid-19 breakthrough infections in vaccinated health care workers. *New England Journal of Medicine*. 2021 Oct 14;385(16):1474-84.
25. Massey D, Berrent D, Krumholz H. Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid: Report from Long Covid Facebook Group Poll. *medRxiv*. 2021 Jan 1.
26. Gorelik Y, Anis E, Edelstein M. Inequalities in initiation of COVID19 vaccination by age and population group in Israel-December 2020-July 2021. *Lancet Reg Health Eur*. 2021 Oct 30:100234.
27. Stephenson T, Pereira SP, Shafran R, De Stavola B, Rojas N, McOwat K, Simmons R, Zavala M, O'Mahoney L, Chalder T, Crawley E. Long COVID-the physical and mental health of children and non-hospitalised young people 3 months after SARS-CoV-2 infection; a national matched cohort study (The CLoCk) Study.
28. Rossi C, Lanuti P, Cicalini I, De Bellis D, Pierdomenico L, Del Boccio P, Zucchelli M, Natale L, Sinjari B, Catitti G, Vespa S. BNT162b2 mRNA vaccination leads to long-term protection from COVID-19 Disease. *Vaccines*. 2021 Oct;9(10):1164.

<b>Table 1. Baseline characteristics of the study population</b>					
<b>Variable</b>	<b>Frequency (n) percent (%)</b>				<b>p-value</b>
	<b>All participants (n=951)</b>	<b>Partially Vaccinated (1 dose) (n=340, 36%)</b>	<b>Fully Vaccinated (2+ doses) (n=294, 31%)</b>	<b>Unvaccinated (n=317, 33%)</b>	
<b>Demographic characteristics</b>					
Age (n= 951)	44 (25) <sup>†</sup>	44 (24.50) <sup>†</sup>	52 (28) <sup>†</sup>	39(17.00) <sup>†</sup>	<b>&lt;0.001</b>
19-35	288 (30.28)	109(32.06)	59 (20.07)	120 (37.85)	
36-60	468 (49.21)	171 (50.29)	135 (45.92)	162 (51.10)	
>60	195 (20.50)	60 (17.65)	100 (34.01)	35 (11.04)	
Sex (n=750)					
Male	283 (37.73)	96 (35.42)	100 (42.37)	87 (35.80)	0.206
Female	467 (62.27)	175 (64.58)	136 (57.63)	156 (64.20)	
Ethnic identity (n=469)					
Jewish	325 (69.30)	118 (66.29)	97 (73.48)	110 (69.18)	0.398
Christian/Muslim Arabs/Druze	144 (30.70)	60 (33.71)	35 (26.52)	49 (30.82)	
Residence (n=460)					
City (Over 20,000 inhabitants)	218 (47.39)	76 (43.68)	64 (48.85)	78 (50.32)	0.374
Town (up to 20,000 residents)	67 (14.57)	26 (14.94)	16 (12.21)	25 (16.13)	
Community residence/ Kibbutz*	154 (33.48)	60 (34.48)	48 (36.64)	46 (29.68)	
Others	21 (4.57)	12 (6.90)	3 (2.29)	06 (3.87)	
Education level(n=434)					
Tertiary institution	248 (57.14)	95 (57.23)	78 (62.90)	75 (52.08)	0.563
Vocational Training	81 (18.66)	28 (16.87)	22 (17.74)	31 (21.53)	
High school	93 (21.43)	37 (22.29)	21 (16.94)	35 (24.31)	
Elementary school	12 (2.76)	6 (3.61)	03 (2.42)	03 (2.08)	
Body mass index (n=458)					
Underweight	10 (2.18)	04 (2.30)	02 (1.53)	04 (2.61)	0.585
Normal	165 (36.03)	63 (36.21)	47 (35.88)	55 (35.95)	
Overweight	175 (38.21)	58 (33.33)	55 (41.98)	62 (40.52)	
Obese	108 (23.58)	49 (28.16)	27 (20.61)	32 (20.92)	
Pre-SARS-CoV-2 infection Chronic Conditions (n=194)					
Hypertension	85 (43.81)	28 (32.94)	41 (48.24)	16 (18.82)	0.008
Asthma	34 (17.53)	08 (23.53)	11 (32.35)	15 (44.12)	
Diabetes mellitus	60 (30.93)	24 (40.00)	24 (32.21)	12 (24.49)	
Chronic obstructive pulmonary disease	15 (07.73)	08 (53.33)	01 (0.067)	06 (40.00)	
Hospitalisation (n=85)	85 (17.31)	35 (19.66)	21 (13.38)	29 (18.59)	0.277
COVID-19 symptomatic at SARS-CoV-2 infection	636 (66.88)	252 (74.12)	167 (56.80)	217 (68.45)	<b>&lt;0.001</b>
Time from beginning of symptoms to responding to the survey (Days)	302 (296) <sup>†</sup>	348.00 (166) <sup>†</sup>	114.50 (340) <sup>†</sup>	246.50 (189) <sup>†</sup>	<b>0.031</b>
*Kibbutz - small collectivist residences, † (median, IQR)					


Post COVID symptoms	Number and proportion experiencing post COVID symptoms, (n (%))			
	All participants (n=951)	Partially Vaccinated (1-dose) (n=340)	Fully Vaccinated (2+ doses) (n=294)	Unvaccinated (n=317)
Fatigue	208 (21.87)	93 (27.35)	33 (11.22)	82 (25.87)
Headache	190 (19.98)	80 (23.53)	41 (13.95)	69 (21.77)
Weakness in arms or legs	128 (13.46)	57 (16.76)	20 (6.08)	51 (16.09)
Persistent muscle pain	98 (10.30)	45 (13.24)	17 (5.78)	36 (11.36)
Loss of concentration	90 (9.46)	44 (12.94)	13 (4.42)	33 (10.41)
Hair loss	88 (9.25)	43 (12.65)	09 (3.06)	36 (11.36)
Problem sleeping	85 (8.94)	42 (12.35)	14 (4.76)	29 (9.15)
Dizziness	74 (7.78)	30 (8.82)	12 (4.08)	32 (10.09)
Persistent cough	70 (7.36)	26 (7.65)	20 (6.80)	24 (7.57)
Shortness of breath	68 (7.15)	29 (8.53)	14 (4.76)	25 (7.89)
Loss of taste	63 (6.62)	20 (5.88)	15 (5.10)	28 (8.83)
Chest pains	61 (6.41)	24 (7.06)	14 (4.76)	23 (7.26)
Pins and needles	60 (6.31)	31 (9.12)	06 (2.04)	23 (7.26)
Palpitations	57 (5.99)	26 (7.65)	12 (4.08)	19 (5.99)
Depression and anxiety	55 (5.78)	19 (5.59)	17 (5.78)	19 (5.99)
Abdominal pain	54 (5.68)	24 (7.06)	08 (2.72)	22 (6.94)
Problems with balance	52 (5.47)	24 (7.06)	07 (2.38)	21 (6.62)
Inability to control body movement	49 (5.15)	22 (6.47)	09 (3.06)	18 (5.68)
Joint pain or swelling	47 (4.94)	22 (6.47)	05 (1.70)	20 (6.31)
Loss of smell	41 (4.31)	09 (2.65)	09 (3.06)	23 (7.26)
Loss of appetite	40 (4.21)	11 (3.24)	12 (4.08)	17 (5.36)
Pain on breathing	40 (4.21)	16 (4.71)	08 (2.72)	16 (5.05)
Nausea and vomiting	37 (3.89)	11 (3.24)	07 (2.38)	19 (5.99)
Constipation	34 (3.58)	12 (3.53)	08 (2.72)	14 (4.42)
Erectile dysfunction	32 (3.36)	12 (3.53)	08 (2.72)	12 (3.79)
Diarrhoea	31 (3.26)	11 (3.24)	05 (1.70)	15 (4.73)
Double vision	29 (3.05)	17 (5.00)	03 (1.02)	09 (2.84)
Problems speaking or communicating	28 (2.94)	15 (4.41)	03 (1.02)	10 (3.15)
Weight loss	28 (2.94)	06 (1.76)	08 (2.72)	14 (4.42)
Tremor / shakiness	27 (2.84)	11 (3.24)	08 (2.72)	08 (2.52)
Problems passing urine	16 (1.68)	06 (1.76)	02 (0.68)	08 (2.52)
Loss of sensation, one side of the body	15 (1.58)	07 (2.06)	02 (0.68)	06 (1.89)
Skin lumps or rashes	13 (1.37)	05 (1.47)	02 (0.68)	06 (1.89)
Problems swallowing or chewing	12 (1.26)	05 (1.47)	03 (1.02)	04 (1.26)
Blood clots in veins	12 (1.26)	05 (1.47)	03 (1.02)	04 (1.26)
Kidney problems	12 (1.26)	05 (1.47)	02 (0.68)	05 (1.58)
Fainting / blackouts	10 (1.05)	04 (1.18)	04 (1.36)	02 (0.63)
Seizures / fits	10 (1.05)	04 (1.18)	03 (1.02)	03 (0.95)
Heart attack & stroke	03 (0.32)	02 (1.87)	01 (1.27)	00 (0.00)

Symptoms and age	Unvaccinated (n=317)	Unadjusted analysis						Adjusted analysis*	
		One dose (n=340)			Two or three vaccine doses (n=294)			Two or three vaccine doses (n=294)	p-value
		n	RR (95% CI)	p-value	n	RR (95% CI)	p-value	RR (95% CI)	p-value
<b>Fatigue</b>									
Overall	82	93	1.057 [0.820-1.364]	0.667	33	0.434 [0.299-0.629]	<b>&lt;0.001</b>	0.361 [0.185-0.706]	<b>0.003</b>
19-35	29	31	1.177 [0.762-1.818]	0.463	13	0.912 [0.513-1.621]	0.753	0.576 [0.185-1.800]	0.343
36-60	46	51	1.078 [0.771-1.509]	0.660	16	0.426 [0.253-0.718]	<b>0.001</b>	0.304 [0.116-0.794]	<b>0.015</b>
>60	7	11	0.833 [0.366-1.895]	0.664	4	0.192 [0.061-0.603]	<b>0.005</b>	0.183 [0.025-1.337]	0.094
<b>Headache</b>									
Overall	95	110	1.081 [0.814-1.435]	0.590	77	0.641 [0.450-0.911]	<b>0.013</b>	0.461 [0.255-0.834]	<b>0.010</b>
19-35	32	34	1.064 [0.686-1.652]	0.781	20	0.949 [0.546-1.649]	0.853	0.367 [0.129-1.042]	0.060
36-60	60	56	1.249 [0.833-1.872]	0.282	40	0.899 [0.559-1.446]	0.660	0.604 [0.276-1.321]	0.206
>60	3	20	0.779 [0.315-1.929]	0.590	17	0.165 [0.045-0.606]	<b>0.007</b>	0.399 [0.036-4.484]	0.457
<b>Weakness in arms and legs</b>									
Overall	103	127	1.042 [0.738-1.472]	0.815	82	0.423 [0.258-0.692]	<b>0.001</b>	0.428 [0.196-0.936]	<b>0.033</b>
19-35	30	41	0.795 [0.409-1.545]	0.499	19	0.565 [0.221-1.447]	0.234	0.801 [0.202-3.186]	0.753
36-60	64	67	1.294 [0.811-2.066]	0.280	46	0.527 [0.270-1.031]	0.061	0.462 [0.161-1.329]	0.152
>60	9	19	0.758 [0.326-1.760]	0.518	17	0.192 [0.061-0.603]	<b>0.005</b>	0.051 [0.006-0.454]	<b>0.008</b>
<b>Persistent muscle pain</b>									
Overall	86	106	1.165 [0.773-1.757]	0.465	80	0.509 [0.292-0.886]	<b>0.017</b>	0.317 [0.114-0.881]	<b>0.028</b>
19-35	23	37	1.001 [0.454-2.672]	0.832	17	0.904 [0.290-2.815]	0.862	0.279 [0.032-2.427]	0.247
36-60	53	56	1.200 [0.726-1.981]	0.477	46	0.573 [0.290-1.131]	0.109	0.420 [0.131-1.351]	0.146
>60	10	13	1.061 [0.331-3.397]	0.921	17	0.192 [0.037-1.009]	0.051	-	-
<b>Loss of concentration</b>									
Overall	55	59	1.243 [0.813-1.901]	0.315	48	0.425 [0.228-0.791]	<b>0.007</b>	0.591 [0.170-2.055]	0.408
19-35	11	21	1.016 [0.485-2.131]	0.966	10	0.782 [0.293-2.091]	0.624	2.456 [0.230-26.171]	0.457
36-60	38	26	1.511 [0.858-2.662]	0.153	31	0.423 [0.172-1.042]	0.061	0.267 [0.306-2.332]	0.232
>60	6	12	1.010 [0.255-4.001]	0.989	7	0.256 [0.044-1.478]	0.103	0.642 [0.002-1.857]	0.110
<b>Hair loss</b>									
Overall	36	43	1.113 [0.735-1.687]	0.612	9	0.270 [0.132-0.550]	<b>&lt;0.001</b>	0.174 [0.056-0.598]	<b>0.005</b>
19-35	17	11	0.712 [0.349-1.453]	0.351	4	0.479 [0.169-1.359]	0.166	0.357 [0.077-1.655]	0.188
36-60	18	28	1.480 [0.854-2.566]	0.163	4	0.266 [0.092-0.767]	<b>0.014</b>	0.142 [0.017-1.177]	0.070
>60	1	1	2.424 [0.281-20.933]	0.421	1	0.385 [0.025-6.002]	0.495	-	-
<b>Sleeping problems</b>									
Overall	29	42	1.350 [0.863-2.113]	0.189	14	0.521 [0.281-0.965]	<b>0.038</b>	0.533 [0.177-1.609]	0.264



19-35	6	7	1.284 [0.445-3.704]	0.643	3	1.017 [0.264-3.924]	0.981	1.181 [0.158-0.840]	0.872
36-60	19	30	1.496 [0.878-2.549]	0.139	8	0.505 [0.228-1.118]	0.092	0.561 [0.136-2.309]	0.423
>60	4	5	0.729 [0.210-2.537]	0.620	3	0.263 [0.062-1.115]	0.070	-	-
<b>Dizziness</b>									
Overall	32	30	0.874 [0.544-1.404]	0.578	12	0.404 [0.212-0.770]	<b>0.006</b>	0.263 [0.087-1.794]	<b>0.018</b>
19-35	9	8	0.979 [0.391-2.447]	0.963	5	1.130 [0.396-3.222]	0.819	0.453 [0.089-2.312]	0.341
36-60	20	19	0.904 [0.502-1.628]	0.737	6	0.370 [0.153-0.896]	<b>0.023</b>	0.244 [0.053-1.119]	0.070
>60	3	3	0.583 [0.124-2.735]	0.494	1	0.128 [0.014-1.196]	0.071	-	-
<b>Persistent cough</b>									
Overall	24	26	1.010 [0.593-1.711]	0.971	20	0.899 [0.507-1.592]	0.714	0.716 [0.281-1.825]	0.483
19-35	10	12	1.321 [0.595-2.935]	0.494	6	1.220 [0.466-3.191]	0.685	1.033 [0.287-3.721]	0.961
36-60	12	10	0.793 [0.353-1.783]	0.575	9	0.899 [0.391-2.067]	0.802	0.788 [0.159-3.896]	0.770
>60	2	4	1.212 [0.232-6.319]	0.819	5	0.962 [0.194-4.756]	0.962	0.145 [0.007-2.825]	0.202
<b>Shortness of breath</b>									
Overall	25	29	1.081 [0.648-1.805]	0.764	14	0.604 [0.320-1.139]	0.199	0.233 [0.065-0.839]	<b>0.026</b>
19-35	10	5	0.771 [0.304-1.954]	0.583	5	1.017 [0.364-2.841]	0.974	0.475 [0.097-2.330]	0.360
36-60	13	19	1.385 [0.707-2.711]	0.343	7	0.646 [0.265-1.573]	0.336	-	-
>60	2	3	0.875 [1.154-4.985]	0.880	2	0.350 [0.051-2.392]	0.284	0.064 [0.002-1.848]	0.909
<b>Recovery from COVID-19</b>									
Overall	170	190	1.019 [0.893-1.163]	0.778	173	1.126 [0.989-1.283]	0.073	0.981 [0.798-1.206]	0.856
19-35	71	60	0.904 [0.732-1.116]	0.347	31	0.857 [0.655-1.122]	0.263	0.769 [0.532-1.112]	0.163
36-60	85	92	1.021 [0.838-1.244]	0.836	67	1.038 [0.839-1.284]	0.732	0.917 [0.657-1.280]	0.611
>60	14	38	1.396 [0.951-2.048]	0.088	75	1.682 [1.181-2.398]	<b>0.004</b>	1.676 [0.796-3.526]	0.174

\*Adjusted for duration of follow-up and asymptomatic population, n= only participants with symptoms



**Figure 1A.** Frequency of most commonly reported symptoms according to vaccination status at SARS-CoV-2 PCR testing

